Trial · NCT03496168
Outcomes20
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events | From first dose to end of treatment + 56 days (Approximately an average of 240 Weeks) | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Had Cardiovascular Death | From first dose to end of study, (approximately 260 weeks) | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Experienced Sudden Death | From first dose to end of study, (approximately 260 weeks) | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Were Hospitalized for Cardiovascular Reasons. | From first dose to end of study, (approximately 260 weeks) | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Heart Failure Due to Systolic Dysfunction, Defined as Asymptomatic LVEF < 50% | From first dose to end of study, (approximately 260 weeks) | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With LVEF < 50% as Measured by Echocardiography. | From first dose to end of study, (approximately 260 weeks) | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Were Experienced Myocardial Infarction | From first dose to end of study, (approximately 260 weeks) | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Ventricular Arrhythmias. | From first dose to end of study, (approximately 260 weeks) | All treated participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Experienced Syncope | From first dose to end of study, (approximately 260 weeks) | All treated participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Experienced Seizures | From first dose to end of study, (approximately 260 weeks) | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Were Experienced Strokes | From first dose to end of study, (approximately 260 weeks) | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With a Change in QT and QTcF Intervals. | From first dose to end of study, (approximately 260 weeks) | All treated participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Post-exercise Left Ventricular Outflow Tract (LVOT) Gradient Over Time | At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252 | Safety Analysis Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Resting Left Ventricular Outflow Tract (LVOT) Gradient Over Time | At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252 | Safety Analysis Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Post Valsalva Left Ventricular Outflow Tract (LVOT) Gradient Over Time | At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252 | Safety Analysis Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Participants With >= 1 NYHA Function Class Improvement | At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252 | Safety Analysis Population | Percentage of Participants | NUMBER |
| PRIMARY | Mean Change From Baseline in the Overall KCCQ PRO Score. | At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252 | Safety Analysis Population | Scores on a Scale | MEAN |
| PRIMARY | Mean Change From Baseline in Serum NT-proBNP. | At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252 | Safety Analysis Population | ng/L | MEAN |
| PRIMARY | Number of Participants Who Received Septal Reduction Therapy | 252 weeks | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Plasma Concentration of Mavacamen Overtime | At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252 | PK Analysis Population | ng/mL | GEOMETRIC_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03496168/outcomes